Baseline characteristics of newly diagnosed patients with multiple myeloma
| . | High risk (N = 16) . | Standard risk (N = 84) . |
|---|---|---|
| Age, y (range) | 67 (48-78) | 63 (32-78) |
| Sex, male:female | 1.3:1 | 2:1 |
| ISS, N = 95 | ||
| Stage I | 12% | 43% |
| Stage 2 | 44% | 47% |
| Stage 3 | 44% | 10% |
| Parameter | Median (range) | Median (range) |
| Hemoglobin, g/dL | 10.8 (7.9-15.6) | 11.1 (6.4-15.6) |
| White blood cells, ×109/L | 5.7 (3.3-8.1) | 5.5 (2.2-56) |
| Platelets, ×109/L | 214 (141-350) | 258 (117-471) |
| Calcium, mg/dL | 9.5 (8-11) | 9.3 (7.3-18.8) |
| Creatinine, mg/dL | 1.3 (0.3-1.7) | 1.1 (0.7-2.4) |
| Lactate dehydrogenase, units/L | 142 (118-286) | 156 (90-317) |
| C-reactive protein, mg/dL | 0.59 (.07-1.8) | 0.3 (.02-74) |
| Monoclonal (M)–Spike, g/dL | 3.5 (0-6.1) | 2.9 (0-6.7) |
| Response rates to lenalidomide-dexamethasone therapy | ||
| CR + VGPR (P = .36) | 38% | 45% |
| ≥ PR (P = .56) | 81% | 89% |
| . | High risk (N = 16) . | Standard risk (N = 84) . |
|---|---|---|
| Age, y (range) | 67 (48-78) | 63 (32-78) |
| Sex, male:female | 1.3:1 | 2:1 |
| ISS, N = 95 | ||
| Stage I | 12% | 43% |
| Stage 2 | 44% | 47% |
| Stage 3 | 44% | 10% |
| Parameter | Median (range) | Median (range) |
| Hemoglobin, g/dL | 10.8 (7.9-15.6) | 11.1 (6.4-15.6) |
| White blood cells, ×109/L | 5.7 (3.3-8.1) | 5.5 (2.2-56) |
| Platelets, ×109/L | 214 (141-350) | 258 (117-471) |
| Calcium, mg/dL | 9.5 (8-11) | 9.3 (7.3-18.8) |
| Creatinine, mg/dL | 1.3 (0.3-1.7) | 1.1 (0.7-2.4) |
| Lactate dehydrogenase, units/L | 142 (118-286) | 156 (90-317) |
| C-reactive protein, mg/dL | 0.59 (.07-1.8) | 0.3 (.02-74) |
| Monoclonal (M)–Spike, g/dL | 3.5 (0-6.1) | 2.9 (0-6.7) |
| Response rates to lenalidomide-dexamethasone therapy | ||
| CR + VGPR (P = .36) | 38% | 45% |
| ≥ PR (P = .56) | 81% | 89% |
ISS indicates international staging system; CR, complete remission; VGPR, very good partial remission; and PR, partial remission.